Cellular Physiology and Biochemistry (Nov 2017)

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer

  • Eleni Politaki,
  • Sofia Agelaki,
  • Stella Apostolaki,
  • Dora Hatzidaki,
  • Areti Strati,
  • Filippos Koinis,
  • Maria Perraki,
  • Georgia Saloustrou,
  • Giannis Stoupis,
  • Galatea Kallergi,
  • Maria Spiliotaki,
  • Tereza Skaltsi,
  • Evi Lianidou,
  • Vassilis Georgoulias,
  • Dimitrios Mavroudis

DOI
https://doi.org/10.1159/000485115
Journal volume & issue
Vol. 44, no. 2
pp. 594 – 606

Abstract

Read online

Background: We directly compared CTC detection rates and prognostic significance, using three different methods in patients with breast cancer (BC). Methods: Early (n=200) and metastatic (n=164) patients were evaluated before initiating adjuvant or first-line chemotherapy, using the CellSearchTM System, an RT-qPCR for CK-19 mRNA detection and by double immunofluorescence (IF) microscopy using A45-B/B3 and CD45 antibodies. Results: Using the CellSearchTM System, 37% and 16.5% of early BC patients were CTC-positive (at ≥1 and ≥2 CTCs/23 ml of blood), 18.0% by RT-qPCR and 16.9% by IF; no agreement was observed between methods. By the CellSearchTM 34.8% and 53.7% (at≥ 5 and ≥ 2 CTCs/7.5 ml) of metastatic patients were CTC-positive, 37.8% by RT-qPCR and 28.5% by IF. A significant agreement existed only between the CellSearchTM and RT-qPCR. In 60.8% of cases, differential EpCAM and CK-19 expression on CTCs by IF could explain the discrepancies between the CellSearchTM and RT-qPCR. CTC-positivity by either method was associated with decreased overall survival in metastatic patients. Conclusion: A significant concordance was observed between the CellSearchTM and RT-qPCR in metastatic but not in early BC. Discordant results could be explained in part by CTC heterogeneity. CTC detection by all methods evaluated had prognostic relevance in metastatic patients.

Keywords